Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement

Area of Science:

• Dermatology
• Pharmacology
• Hair Restoration Science

Background:

• Small studies suggest low-dose oral minoxidil (LDOM) is a safe and effective off-label treatment for hair loss.
• Standardized guidelines and large-scale trials for LDOM in hair loss are currently lacking.

Purpose of the Study:

• To establish an international expert consensus statement for the off-label prescribing of low-dose oral minoxidil (LDOM) for patients experiencing hair loss.

Main Methods:

• A comprehensive literature review on LDOM's pharmacology, safety, and efficacy in hair loss was conducted.
• A modified Delphi consensus process involved 43 international hair loss specialists over four survey rounds.
• Consensus was defined as at least 70% agreement on a 5-point Likert scale for 76 items.

Main Results:

• Consensus was reached on LDOM indications, comparisons with topical minoxidil, adult and adolescent dosing, contraindications, precautions, baseline evaluation, monitoring, and adjunctive therapies.
• Areas lacking consensus included pediatric use and dosing (children under 12) and specific LDOM titration protocols.

Conclusions:

• This consensus statement offers practical guidance for clinicians using off-label LDOM for hair loss in adults and adolescents.
• Further research is needed, particularly on pediatric LDOM use, comparative efficacy with topical minoxidil, and long-term safety.
• Recommendations will be updated as more evidence-based data becomes available.